83.5%
logic-gated Tmod chimeric antigen receptor T-cell therapiesadvanced solid malignancyBASECAMP-1BASECAMP-1A2 BiotherapeuticsTempus AIadvanced solid malignancies
…udy to identify patients eligible for interventional studies of logic-gated Tmod chimeric antigen receptor T-cell therapies. Eligible patients for these interventional trials have an adva…